Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Biliary Tract Neoplasms × atezolizumab × Clear all

Phase

Phase 2 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 11 Small Cell Lung Carcinoma 6 Lung Neoplasms 6 Carcinoma, Hepatocellular 6 Breast Neoplasms 6 Urinary Bladder Neoplasms 5 Carcinoma, Transitional Cell 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Neoplasms 4 Neoplasm Metastasis 4 Melanoma 4 Glioblastoma 4 Advanced Solid Tumor 4 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Cancer 2 Small Cell Lung Cancer Extensive Stage 2 Sarcoma 2 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Leukemia, Myeloid, Acute 2 Gliosarcoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2

Interventions

Gemcitabine 11 Cisplatin 9 pembrolizumab 6 durvalumab 4 Oxaliplatin 3 Nivolumab 3 Leucovorin 3 Injections 3 Immune Checkpoint Inhibitors 3 Fluorouracil 3 camrelizumab 2 Paclitaxel 2 Docetaxel 2 Cetuximab 2 Carboplatin 2 Capecitabine 2 130-nm albumin-bound paclitaxel 2 tremelimumab 1 surufatinib 1 spartalizumab 1 silmitasertib 1 regorafenib 1 pertuzumab 1 manganese chloride 1 lenvatinib 1 irinotecan sucrosofate 1 devimistat 1 derazantinib 1 binimetinib 1 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05052099 2025-09-29

COMBATBIL

University Hospital, Essen

Phase 1/2 Completed

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡